免疫检查点抑制剂相关不良事件中的疼痛谱:基于参考资料的演变,特征和管理挑战
Qiongqian Li1, Shunrong Zhang1, Tongze Cai2
1Guangxi International Zhuang Medicine Hospital, Affiliated to Guangxi University of Chinese Medicine, Nanning, China.
概括
免疫检查点抑制剂 (ICI) 疼痛管理是复杂的,需要仔细平衡治疗疗效和副作用控制. 这项研究分析了研究趋势,以指导开发类固醇节约策略,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 疼痛医学 医学 疼痛医学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但与免疫相关的不良事件 (irAEs),特别是疼痛,存在重大临床挑战.
- ICI诱导的疼痛具有独特的机制和表现,往往需要降低剂量,这可能会损害治疗疗效.
- 管理ICI相关的疼痛需要平衡免疫抑制与止痛,同时避免长期使用类固醇的有害影响,使类固醇节约策略成为一个关键的研究领域.
研究的目的:
- 进行对与免疫检查点抑制剂 (ICI) 相关的免疫相关不良事件 (irAEs) 疼痛研究的文献分析.
- 检查与ICI相关IRAE疼痛谱相关的研究趋势,进展,特征和管理挑战.
- 确定当前的焦点和该领域的未来方向.
主要方法:
- 一个系统的文献搜索从Web of Science核心集合中确定了484个相关出版物.
- 用VOSviewer和CiteSpace软件进行了图书统计分析.
- 关键分析包括协作网络,关键词的共同出现,引用关系和引用爆发检测.
主要成果:
- 瘤学是主要的学科,有美国机构的重大贡献,并强调国际合作.
- 目前的研究重点是不同ICI的疼痛表型,其免疫机制,以及将ICI相关的疼痛与其他疼痛类型区分开来.
- 关键的挑战包括早期识别ICI-疼痛,平衡irAE控制与类固醇使用,并开发类固醇节约策略和预测生物标志物,以精确管理疼痛.
结论:
- 本文献计量研究提供了关于ICI相关疼痛的知识格局和研究趋势的全面概述.
- 它强调了跨学科合作的关键需求,以应对临床挑战.
- 未来的方向强调推进个性化,基于精度的治疗策略,以管理接受ICI的患者的疼痛.
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Inflammatory Bowel Disease IV: Pharmacological Management
860
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
860
Acute Pancreatitis II: Clinical Manifestations and Management
960
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
960
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288


